Acute Coronary Syndromes
Conditions
Brief summary
Currently available therapies to treat Acute Coronary Syndromes(ACS) have several limitations including; the relatively long treatment duration required before apparent significant benefit; the inability to achieve reversal of the atherosclerotic process; and poor patient compliance due to chronicity of therapy. This study will assess the effects of rHDL compared with placebo on indices of atherosclerosis progression and regression as assessed with intravascular ultrasound (IVUS) in patients after acute coronary syndromes (ACS).
Interventions
DRUGrHDL
Sponsors
CSL Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female 30 - 75 years of age * Recent acute coronary syndrome, defined as unstable angina, non-Q wave myocardial infarction, or ST elevation indicative of myocardial infarction, within the last 14 days
Exclusion criteria
* \>50% stenosis by visual angiographic estimation in the left main artery * Renal insufficiency * Severe liver disease * Congestive heart failure as defined by the NYHA classification as functional Class III or Class IV * Previous or planned coronary artery bypass surgery
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety | — |
Countries
Canada
Outcome results
None listed